Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2020-06-18 Regulatory Filings
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Nytt patentbeviljande i Japan för Episurf Medical
Regulatory Filings Classification · 1% confidence The document is a short announcement (1596 characters) written in Swedish regarding a new patent granted in Japan for Episurf Medical. It details the patent's subject matter and includes standard contact and company information. It is not a comprehensive financial report (like 10-K or IR), nor is it a management change (MANG), dividend notice (DIV), or earnings release (ER). Since it announces a specific, non-financial regulatory/legal event (patent grant) that doesn't fit the specific categories like LTR (Legal Proceedings Report), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings), as it is an official public disclosure required under market regulations (EU's Market Abuse Regulation mentioned at the end).
2020-06-18 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage for an issuer (Episurf Medical AB) held by a specific entity (Avanza Bank Holding AB for Avanza Pension). It explicitly states the 'Reason for major shareholding notification' as 'Sell' and provides the 'Before' and 'After' transaction details, including the resulting share count and percentage (4.97%). This structure perfectly matches the definition of a Major Shareholding Notification, which reports changes in significant ownership levels crossing thresholds. The corresponding code is MRQ.
2020-06-17 English
New European patent approval for Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces a specific, non-financial event: the intention to grant a European patent for Episurf Medical's technology. It includes contact information, a brief company description, and a concluding statement about compliance with the EU Market Abuse Regulation (MAR) regarding the dissemination of this information. This type of announcement, which is a specific operational or legal update that doesn't fit into standard financial reports (10-K, IR, ER) or corporate governance filings (DEF 14A, CGR), is best classified as a general regulatory announcement or filing. Since it is not a standard financial report, dividend notice, management change, or insider trade, the most appropriate fallback category is Regulatory Filings (RNS). The document length is short (1744 chars), but it is the primary content, not an announcement *about* another report, so the RPA rule does not strictly apply here, although RNS is the best fit for miscellaneous regulatory news.
2020-06-10 English
Nytt patentbeviljande i Europa för Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces that the European Patent Office (EPO) intends to grant a new European patent to Episurf Medical for technology related to their Episealer® implants. It includes a quote from the COO and standard company information. This is a specific announcement regarding intellectual property/patents, which does not fit neatly into the primary financial reporting categories (10-K, IR, ER, etc.). Among the provided definitions, 'Legal Proceedings Report (LTR)' covers lawsuits and regulatory actions, but a patent grant is generally considered an IP/corporate development announcement. Since there is no specific 'Intellectual Property' or 'Patent Grant' code, and it is a formal announcement of a regulatory/legal development concerning the company's assets, the most appropriate fallback category is 'Regulatory Filings (RNS)' as it is a mandatory public disclosure under EU market abuse regulation ('EU:s marknadsmissbruksförordning').
2020-06-10 Swedish
Nytt patentbeviljande i Europa för Episurf Medical
Regulatory Filings Classification · 1% confidence The document is a short announcement in Swedish regarding a new patent granted in Europe for Episurf Medical. It details the patent's subject matter and includes quotes from management. The final paragraph explicitly states that the information is being made public according to the EU Market Abuse Regulation (MAR) and provides a time and date of release (June 8, 2020). This structure—a brief announcement of a specific corporate event (patent grant) released under regulatory obligation—does not fit the specific categories like 10-K, ER, or IR. Since it is a regulatory disclosure that doesn't fit the more specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements.
2020-06-08 Swedish
New European patent approval for Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces a specific corporate event: the European patent office's intention to grant a new patent to Episurf Medical. It provides details about the patent, quotes management, and includes standard 'About Us' information. Crucially, the final paragraph states: "This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation." This strongly suggests a mandatory regulatory disclosure concerning a material event (patent grant). Since there is no specific category for 'Patent Grant Announcement,' and it is a mandatory disclosure under MAR, it fits best into the general regulatory announcement category, RNS (Regulatory Filings), which serves as a fallback for miscellaneous regulatory disclosures that don't fit the primary financial report types (10-K, IR, ER, etc.). The document is not a full report, a management change, or a financing event.
2020-06-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.